Maryland is currently home to 2692 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Maryland Oncology Hematology, Silver Spring, Maryland
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Retinal Blood Flow and Autoregulation
NCT05344274
Recruiting
The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
05/06/2024
Locations: University of Maryland Faculty Physicians, Inc, Baltimore, Maryland
Conditions: Glaucoma
Register for Updates
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT04527900
Recruiting
A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Endometrial Cancer
Register for Updates
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Recruiting
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
NCT06403605
Recruiting
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Foot and Ankle Specialists of the Mid Atlantic, Frederick, Maryland
Conditions: Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Register for Updates
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
NCT05845593
Recruiting
This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including ANA, anti-DNA, anti-RNP and complement components C3 and C4, as well as Patient Reported Outcomes capturing pain, fatigue and Health-Related Quality of Life. The test will be administered on one occa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Maryland School of Medicine, Baltimore, Maryland
Conditions: Lupus Erythematosus, Systemic
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
05/01/2024
Locations: University of Maryland Children's Hospital, Baltimore, Maryland
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Maryland Oncology Hematology, P.A., Silver Spring, Maryland
Conditions: Endometrial Cancer
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Tender Loving Care for Recurrent Pregnancy Loss
NCT06182878
Recruiting
The goal of this investigational study is to evaluate participation in a weekly, interactive, tender loving care messaging platform impact on pregnancy outcomes in patients with recurrent pregnancy loss. The main questions it aims to answer are: (1) does participation in weekly, interactive tender loving care messages increase live birth rates in patients with recurrent pregnancy loss? (2) Does participation in weekly, interactive tender loving care messages increase patients' quality of life?... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
04/29/2024
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Recurrent Pregnancy Loss
Register for Updates
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
NCT05458544
Recruiting
Phase 1: The objective of the Phase 1 part of the clinical trial is to verify safety and tolerability (dose-limiting toxicity \[DLT\], maximum tolerated dose \[MTD\]) of a single 3.7 Giga-Becquerel (GBq) dose with the potential for one dose level de-escalation to 2.775 GBq if necessary, to determine the recommended \[177Lu\]Ludotadipep dose for use in the Phase 2a part of the trial. Phase 2a: The objective of the Phase 2a part of the trial is to evaluate safety and efficacy for repeated adminis... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Recruiting
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Continental Clinical Solutions, LLC, Towson, Maryland
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Register for Updates